Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia

Clinical Infectious Diseases(2024)10.1093/cid/ciae261Source: DataRank Database

Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0.837. It has been cited 18 times, with 16 citing works in its 1-hop citation network.

N/A

0.837DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access18 citations · 16 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04612452

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (23 grants)Impact (FWCI 5.49)OA: hybridTopics (69)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 53%Citation Network 47%

Base Score Contribution

0.442

From this paper's citation signal

Citation Network Contribution

0.395

From 7 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 16 citers.

Brief Report: Resistance to Dolutegravir in Treatment-Experienced Patients in South Africa: A Retrospective Cohort Study
JAIDS Journal of Acquired Immune Deficiency Syndromes20253 citations16 referencesContributes 0.087
Predictors of treatment-emergent resistance to dolutegravir
The Lancet HIV20255 citations21 referencesContributes 0.085
Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial
The Lancet Global Health20245 citations26 referencesContributes 0.069
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
JAMA2024226 citations89 referencesContributes 0.061
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study
The Lancet HIV20253 citations24 referencesContributes 0.058

Authors (16)

Jacqueline Huwa ORCID,Guy Muula,Geldert Chiwaya,E. de la Banda,Shameem Buleya

Live enrichment

PubMed:38847281 PMC:PMC11797054 OpenAlex:https://openalex.org/W4399402064

National Institute of Allergy and Infectious Diseases

Grant: R01AI152772

Swiss National Science Foundation

Grant: 32FP30_207285

Swiss National Science Foundation

Grant: 324730_207957

Fogarty International Center

Grant: U01AI069924

FIC NIH HHS

Grant: D43 TW010060

Swiss National Science Foundation

Grant: 207957

The Evolutionary Epidemiology of HIV Elimination

Swiss National Science Foundation

Grant: 207285

Forschungspauschale Forschungsratspräsident SNF

NHLBI NIH HHS

NIDDK NIH HHS

National Institute of Mental Health

Lighthouse Trust

National Institute on Drug Abuse

NIMH NIH HHS

National Institute on Alcohol Abuse and Alcoholism

Division of Cancer Epidemiology and Genetics of the National Cancer Institute

IeDEA-SA

NIH

National Heart, Lung, and Blood Institute

National Institute of Diabetes and Digestive and Kidney Diseases

NIDA NIH HHS

Eunice Kennedy Shriver National Institute of Child Health and Human Development

CIDRZ

NIAAA NIH HHS

FWCI

5.49

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1093/cid/ciae261

publisherhttps://doi.org/10.1093/cid/ciae261

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae261/58162850/ciae261.pdf

publisherhttps://academic.oup.com/cid/article-pdf/80/1/120/58162850/ciae261.pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38847281

Fields of Study

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment03 medical and health sciences0303 health sciences

MeSH Terms

DolutegravirAdultFemaleHeterocyclic Compounds, 3-RingHumansMalawiMaleMiddle AgedOxazinesPiperazinesPyridonesViremiaZambiaHIV-1HIV InfectionsTreatment FailureLamivudineAnti-HIV AgentsHIV Integrase InhibitorsViral LoadAntiretroviral Therapy, Highly ActiveDrug Resistance, ViralYoung AdultDrug Substitution

Keywords

DolutegravirMedicineAntiretroviral therapyDrug resistanceVirologyAntiretroviral drugHuman immunodeficiency virus (HIV)DrugIntensive care medicineViral loadPharmacologyMicrobiologyHIVSouthern Africa10028 Institute of Medical VirologyAdultMaleMalawiAnti-HIV AgentsPyridonesZambia610 Medicine & healthHIV Infections142-005 142-005Piperazines10234 Clinic for Infectious DiseasesYoung Adult616Drug Resistance, ViralOxazinesHumansTreatment FailureViremia610 Medicine & healthMiddle AgedHIV Southern Africa antiretroviral therapy dolutegravir drug resistanceLamivudineHIV-1FemaleHeterocyclic Compounds, 3-Ring

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being